New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
11:59 EDTCELGCelgene weakness an overreactions, says Wells Fargo
Wells Fargo said Celgene weakness related to the upcoming Markman hearing and the UK's The National Institute for Health and Care Excellence guidance that thalidomide vs. Revlimid should be considered in most second line MM patients is an overreaction. The firm said the Markman hearing has been an overhang but there are many steps needed before a final outcome and that the UK's decision is not meaningful given current reimbursement is only for 3rd+ line anyway. The firm would use weakness in Celgene as a buying opportunity and reiterates its Outperform rating.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
13:21 EDTCELGAlphabet, Celgene, others could rise 20% over next year, Barron's says
Subscribe for More Information
November 20, 2015
10:52 EDTCELGFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 17, 2015
08:22 EDTCELGSignificant Celgene overhang removed, says JMP Securities
Subscribe for More Information
November 16, 2015
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information
November 13, 2015
11:02 EDTCELGCelgene calls active on renewed takeover chatter
Celgene November weekly 111 and 112 calls are active on total call volume of 9K contracts (3K puts) on renewed takeover chatter. November weekly call option implied volatility is at 82, November is at 42, December is at 35; compared to its 52-week range of 23 to 54. Active call volume suggests traders taking positions for large price movement.
10:58 EDTCELGRumor: Celgene moves up on renewed takeover chatter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use